United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

BioNTech SE

Johnson & Johnson

Moderna

Novavax

What's the Best Way to Invest in Coronavirus Vaccine Stocks?

In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the third quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.

Will Pfizer's (PFE) Oncology Drugs Drive Its Q3 Earnings?

It's important to look at the big picture.

Are Coronavirus Vaccine Stocks Too Expensive?

The coronavirus vaccine candidates attempt to trick the body in different ways.

What Are the Differences Between the Leading Coronavirus Vaccine Candidates?

Two are huge drugmakers and one is a small biotech with tremendous growth potential.

3 Coronavirus Vaccine Stocks That Especially Stand Out Right Now

Gilead Sciences

Regeneron Pharmaceuticals

It could translate to good news for biotechs with COVID-19 therapies.

Here's the Biggest Misconception About Coronavirus Vaccines

Which stock wins between this up-and-coming biotech and a longtime pharma giant?

Better Coronavirus Stock: Moderna vs. Pfizer

A coronavirus vaccine could be available sooner than you might think.

What's the Timeline for FDA Emergency Use Authorization of Coronavirus Vaccines?

The upside is huge, but the risks could be larger than normal.

Are Consumers and Investors Protected Against COVID-19 Vaccine Risks?

One analyst initiates coverage with a robust buy recommendation on the shares.

Pfizer Stock: Headed to $42?

International Business Machines Corp (NYSE: IBM) and Pfizer Inc (NYSE: PFE) published results in The Lancet eClinical Medicine on the early detection of Alzheimer's Disease. What Happened: Researchers from the two companies designed artificial intelligence to detect language data to predict whether a person would develop Alzheimer's disease, according to a Thursday press release.

IBM, Pfizer Collaborate On Early Alzheimer's Detection With Artificial Intelligence

President Trump said a coronavirus vaccine is weeks away in his first remarks during Thursday's presidential debate.

COVID-19 vaccine weeks away, J&J, Moderna, Pfizer leading race

Key Takeaways:Progress on a COVID-19 vaccine is front and center as health firms prepare to report Q3 results Moderna, Pfizer among the closely watched companies expected to have vaccine data soon Gilead earnings ahead after treatment gets bad news from World Health Organization Everyone complain.

Vaccine Watch: Investors Await Pfizer, Moderna Results, Monitor Gilead Treatment

PALO ALTO, Calif.--(BUSINESS WIRE)--Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that Pfizer's Hospital Business has agreed to acquire Arixa. Arixa's lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part of Avycaz® (sold by Pfizer as Zaficefta® outside the United States), an intravenous-only combination with ce

Arixa Pharmaceuticals Announces Acquisition by Pfizer's Hospital Business

Chevron

Walmart

Here are top stocks to buy that have a robust dividend pay-out in addition to being relatively low beta stocks. Simply put, these are dividend value creators.

4 Top Dividend Stocks That'll Pay You Better Than ‘Exciting Trailblazers'

The mRNA coronavirus vaccine in development by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is poised for an emergency use authorization application, according to SVB Leerink.  The Pfizer Analyst: Geoffrey Porges has a Market Perform rating on Pfizer shares.

Pfizer's COVID-19 Vaccine Candidate Primed For $3.5B In 2021 Sales: Analyst

The prices for the first batches of the vaccine have already been set.

How Profitable Is Coronavirus Vaccine Development?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the full analysis from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease.1 The data from this pivotal trial were presented as part of IDWeek's virtual 2020 medical congress, along with data from a Phase 2 proof-of-concept study in infants

Data From Pfizer's Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020

JPMorgan Chase & Co

AT&T

Look at cyclical stocks that pay dividends, not classic defensive picks.

These are the 3 best dividend yield investments for 2021

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

The first one could be just a few days away.

3 Critical Near-Term Milestones to Watch With Pfizer's Coronavirus Vaccine

Pfizer (PFE) closed at $37.80 in the latest trading session, marking a -0.4% move from the prior day.

Pfizer (PFE) Stock Moves -0.4%: What You Should Know

Alphabet

John Bean Technologies

Major League Baseball punished the Houston Astros for the way they stole opponents' signs. But there's no penalty for an investment manager stealing ideas from another manager.

Does Stolen Fruit Taste Better? Check Out My Purloined Portfolio

Cisco Systems

Dominion Energy

Realty Income Corp

People's United Financial

Philip Morris

Starbucks

Scotts Miracle-Gro

Target

T. Rowe Price Group

Walgreens

Exxon Mobil

In September, we received $1,941.89 in dividend income, a 15.7% increase compared to last year.

Dividend Income Summary: Bert's September 2020 Summary

The vaccines are ready to be rolled out worldwide should regulators approve it.

News for Pfizer Stock (PFE)